Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial

Novartis’ Ionis-partnered drug designed to lower levels of Lp(a), a known cardiovascular risk factor, failed to reduce patients’ risk of a heart attack, stroke, or other major cardiovascular event in the first late-stage test for a drug meant to tackle the mysterious molecule.